212 related articles for article (PubMed ID: 37103916)
21. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.
Gianni L; Pienkowski T; Im YH; Tseng LM; Liu MC; Lluch A; Starosławska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi GV; Magazzù D; McNally V; Douthwaite H; Ross G; Valagussa P
Lancet Oncol; 2016 Jun; 17(6):791-800. PubMed ID: 27179402
[TBL] [Abstract][Full Text] [Related]
22. Pathologic Complete Response with Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Trastuzumab and Pertuzumab in Patients with HER2-Positive Early Stage Breast Cancer: A Single Center Experience.
Singh JC; Mamtani A; Barrio A; Morrow M; Sugarman S; Jones LW; Yu AF; Argolo D; Smyth LM; Modi S; Schweber S; Boafo C; Patil S; Norton L; Baselga J; Hudis CA; Dang C
Oncologist; 2017 Feb; 22(2):139-143. PubMed ID: 28167568
[TBL] [Abstract][Full Text] [Related]
23. Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab.
Gion M; García-Mosquera JJ; Pérez-García JM; Peg V; Ruiz-Borrego M; Stradella A; Bermejo B; Guerrero JA; López-Montero L; Mancino M; Rodríguez-Morató J; Antonarelli G; Sampayo-Cordero M; Llombart-Cussac A; Cortés J
Breast Cancer Res Treat; 2024 Jun; 205(3):589-598. PubMed ID: 38456970
[TBL] [Abstract][Full Text] [Related]
24. Efficacy of neoadjuvant treatment with or without pertuzumab in patients with stage II and III HER2-positive breast cancer: a nationwide cohort analysis of pathologic response and 5-year survival.
van der Voort A; Liefaard MC; van Ramshorst MS; van Werkhoven E; Sanders J; Wesseling J; Scholten A; Vrancken Peeters MJTFD; de Munck L; Siesling S; Sonke GS
Breast; 2022 Oct; 65():110-115. PubMed ID: 35921798
[TBL] [Abstract][Full Text] [Related]
25. Pathological complete response to neoadjuvant trastuzumab and pertuzumab therapy is related to human epidermal growth factor receptor 2 (HER2) amplification level in HER2-amplified breast cancer.
Choi JH; Jeon CW; Kim YO; Jung S
Medicine (Baltimore); 2020 Nov; 99(46):e23053. PubMed ID: 33181670
[TBL] [Abstract][Full Text] [Related]
26. A randomized, 3-arm, neoadjuvant, phase 2 study comparing docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP), TCbHP followed by trastuzumab emtansine and pertuzumab (T-DM1+P), and T-DM1+P in HER2-positive primary breast cancer.
Masuda N; Ohtani S; Takano T; Inoue K; Suzuki E; Nakamura R; Bando H; Ito Y; Ishida K; Yamanaka T; Kuroi K; Yasojima H; Kasai H; Takasuka T; Sakurai T; Kataoka TR; Morita S; Ohno S; Toi M
Breast Cancer Res Treat; 2020 Feb; 180(1):135-146. PubMed ID: 31953696
[TBL] [Abstract][Full Text] [Related]
27. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM; Ewer MS; Viale G; Delaloge S; Ferrero JM; Verrill M; Colomer R; Vieira C; Werner TL; Douthwaite H; Bradley D; Waldron-Lynch M; Kiermaier A; Eng-Wong J; Dang C;
Ann Oncol; 2018 Mar; 29(3):646-653. PubMed ID: 29253081
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and Safety of Dual Anti-HER2 Blockade and Docetaxel With or Without Carboplatin as Neoadjuvant Regimen for Treatment of HER2-Positive Breast Cancer.
Lin B; Fan J; Liu F; Wen Y; Li J; Gao F; Zhang Y; Feng G; Du X; Chen W
Technol Cancer Res Treat; 2023; 22():15330338231218152. PubMed ID: 38031361
[No Abstract] [Full Text] [Related]
29. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study).
González-Santiago S; Saura C; Ciruelos E; Alonso JL; de la Morena P; Santisteban Eslava M; Gallegos Sancho MI; de Luna A; Dalmau E; Servitja S; Ruiz Borrego M; Chacón JI
Breast Cancer Res Treat; 2020 Nov; 184(2):469-479. PubMed ID: 32876911
[TBL] [Abstract][Full Text] [Related]
30. Effect of Denosumab Added to 2 Different nab-Paclitaxel Regimens as Neoadjuvant Therapy in Patients With Primary Breast Cancer: The GeparX 2 × 2 Randomized Clinical Trial.
Blohmer JU; Link T; Reinisch M; Just M; Untch M; Stötzer O; Fasching PA; Schneeweiss A; Wimberger P; Seiler S; Huober J; Thill M; Jackisch C; Rhiem K; Solbach C; Hanusch C; Seither F; Denkert C; Engels K; Nekljudova V; Loibl S;
JAMA Oncol; 2022 Jul; 8(7):1010-1018. PubMed ID: 35588050
[TBL] [Abstract][Full Text] [Related]
31. Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Lavasani SM; Somlo G; Yost SE; Frankel PH; Ruel C; Cui Y; Murga M; Tang A; Martinez N; Kruper L; Tumyan L; Schmolze D; Yeon C; Yuan Y; Waisman JR; Mortimer J
Cancer; 2023 Mar; 129(5):740-749. PubMed ID: 36517940
[TBL] [Abstract][Full Text] [Related]
32. Retrospective study of the efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab/pertuzumab (TCH-P) in nonmetastatic HER2-positive breast cancer.
Tiwari SR; Mishra P; Raska P; Calhoun B; Abraham J; Moore H; Budd GT; Fanning A; Valente S; Stewart R; Grobmyer SR; Montero AJ
Breast Cancer Res Treat; 2016 Jul; 158(1):189-193. PubMed ID: 27324504
[TBL] [Abstract][Full Text] [Related]
33. Neoadjuvant pertuzumab plus trastuzumab in combination with anthracycline- free chemotherapy regimen in patients with HER2 positive breast cancer-Real-world data from a single center in India.
Arora S; Gogia DA; Deo S; Sharma D; Mathur SR
Cancer Treat Res Commun; 2021; 29():100483. PubMed ID: 34710849
[TBL] [Abstract][Full Text] [Related]
34. Dual HER2-blockade with pertuzumab and trastuzumab in HER2-positive early breast cancer: a subanalysis of data from the randomized phase III GeparSepto trial.
Loibl S; Jackisch C; Schneeweiss A; Schmatloch S; Aktas B; Denkert C; Wiebringhaus H; Kümmel S; Warm M; Paepke S; Just M; Hanusch C; Hackmann J; Blohmer JU; Clemens M; Dan Costa S; Gerber B; Engels K; Nekljudova V; von Minckwitz G; Untch M;
Ann Oncol; 2017 Mar; 28(3):497-504. PubMed ID: 27831502
[TBL] [Abstract][Full Text] [Related]
35. Axillary response according to neoadjuvant single or dual human epidermal growth factor receptor 2 (HER2) blockade in clinically node-positive, HER2-positive breast cancer.
Cha C; Ahn SG; Kim D; Lee J; Park S; Bae SJ; Kim JY; Park HS; Park S; Kim SI; Park BW; Jeong J
Int J Cancer; 2021 Oct; 149(8):1585-1592. PubMed ID: 34213778
[TBL] [Abstract][Full Text] [Related]
36. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
Fernandez-Martinez A; Rediti M; Tang G; Pascual T; Hoadley KA; Venet D; Rashid NU; Spears PA; Islam MN; El-Abed S; Bliss J; Lambertini M; Di Cosimo S; Huobe J; Goerlitz D; Hu R; Lucas PC; Swain SM; Sotiriou C; Perou CM; Carey LA
JAMA Oncol; 2024 May; 10(5):603-611. PubMed ID: 38546612
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of factors predicting pathologic complete response in locally advanced HER2 positive breast cancer treated with neoadjuvant pertuzumab, trastuzumab and chemotherapy; Real life data.
Ates O; Oksuzoglu OB; Aktas BY; Karadag I; Esen S; Karakaya S; Uncu D; Erol C; Gurbuz M; Yalcin B; Aksoy S
J BUON; 2021; 26(4):1398-1404. PubMed ID: 34564997
[TBL] [Abstract][Full Text] [Related]
38. Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE).
de Haas SL; Slamon DJ; Martin M; Press MF; Lewis GD; Lambertini C; Prat A; Lopez-Valverde V; Boulet T; Hurvitz SA
Breast Cancer Res; 2023 Jan; 25(1):2. PubMed ID: 36631725
[TBL] [Abstract][Full Text] [Related]
39. Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group.
Wildiers H; Tryfonidis K; Dal Lago L; Vuylsteke P; Curigliano G; Waters S; Brouwers B; Altintas S; Touati N; Cardoso F; Brain E
Lancet Oncol; 2018 Mar; 19(3):323-336. PubMed ID: 29433963
[TBL] [Abstract][Full Text] [Related]
40. BluePrint molecular subtypes predict response to neoadjuvant pertuzumab in HER2-positive breast cancer.
Liefaard MC; van der Voort A; van Ramshorst MS; Sanders J; Vonk S; Horlings HM; Siesling S; de Munck L; van Leeuwen AE; Kleijn M; Mittempergher L; Kuilman MM; Glas AM; Wesseling J; Lips EH; Sonke GS
Breast Cancer Res; 2023 Jun; 25(1):71. PubMed ID: 37337299
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
